Clariant is ramping up its Clear Lake site to produce pharmaceutical-grade polyethylene glycol (PEG) excipients under full excipient GMP compliance, enhancing availability and reliability for North American customers while extending reach into Latin America. 

 

The multi-phase expansion tackles critical industry priorities, including supply-chain security, continuity, and responsiveness, underscoring Clariant’s long-term commitment to the U.S. pharmaceutical market.

 

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production, a major milestone in the company’s healthcare growth strategy. By building regional production capabilities, Clariant is creating a more resilient, responsive supply chain for pharmaceutical manufacturers across the continent.

 

Regional manufacturing delivers immediate operational benefits: shorter lead times, faster market response, reduced inventory costs, and competitive pricing. It also strengthens supply continuity, giving pharmaceutical companies the predictability needed for complex production schedules and regulatory compliance.

 

"This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry," said Vaios Barlas, Head of Health Care at Clariant. "In addition to greater manufacturing capacity, we're fundamentally transforming how we serve our customers by bringing production closer to their operations and accelerating more responsive, collaborative relationships."

 

The Clear Lake upgrade meets the pharmaceutical industry’s highest quality, safety, and regulatory standards.